Vital signs
Ask whether heart rate, blood pressure, temperature, breathing, and level of responsiveness are monitored when relevant—and what triggers escalation.
Ibogaine or ayahuasca · decision framework
Risk & Screening
Safety questions are not a barrier to a decision. They are the part of the decision that asks whether a particular substance, setting, and person’s circumstances can be responsibly considered at all.
This page is informational. Individual risk assessment requires a licensed clinician who can review medical history, medication use, and current circumstances.
Two distinct risk profiles
Start with the risks that do not overlap.
“A careful comparison does not reduce safety to a preference for one experience over another.”
Ibogaine and ayahuasca raise different medical and logistical questions. A decision framework should begin by separating those questions rather than treating either substance as a generic “psychedelic” category. The broader decision framework for weighing ibogaine and ayahuasca is most useful when safety concerns are placed before expectations about outcomes.
With ibogaine, cardiac conduction issues and QT prolongation risk deserve particular attention. The FDA’s discussion of QT-related abnormal heart rhythms illustrates why medication effects on cardiac electrical activity are taken seriously. A personal history, current medications, electrolyte status, and an ECG are all relevant parts of a clinician-led review.
Ayahuasca involves MAOI-containing preparations and may raise concerns about serotonergic medicines and serotonin syndrome. The clinical concept of serotonin syndrome is relevant because combinations that affect serotonin can become dangerous. This is not a reason to alter medication independently; it is a reason to bring a complete medication history to a qualified prescriber.
Interactive screening module
Questions a credible screening process should be able to answer.
Open each area for the purpose behind the question. These are discussion prompts, not a substitute for medical judgment.
Cardiac history and ECG
For ibogaine, screening should account for known cardiac disease, fainting, arrhythmia history, family history that may matter, and medicines that can affect rhythm. An ECG is a basic way clinicians assess electrical conduction, while its interpretation belongs in an appropriately qualified setting.
Complete medication review
A useful review includes prescriptions, over-the-counter medicines, supplements, and recent substance use. It should specifically consider medicines with cardiac, serotonergic, or MAOI-related implications rather than relying on a partial list.
Liver function and physical health
Liver function can matter when substances and medications are metabolized. A credible process should not treat laboratory review as a decorative step; it should explain what is being assessed and how findings change the conversation.
Psychiatric history and support
Psychiatric history, current mental state, prior episodes of mania or psychosis, trauma history, and available support all shape risk. The point is not to apply a label, but to identify whether the setting has the capacity for careful, individual consideration.
Before any setting is considered
Assessment should be more than a questionnaire.
Good screening has a practical function: it gives the person and any clinician involved enough information to identify unresolved risk, ask follow-up questions, or decide that a proposed setting is not appropriate.
For an overview of what an electrocardiogram measures, the National Heart, Lung, and Blood Institute’s ECG guidance describes its role in recording the heart’s electrical activity. The value of any test, however, depends on qualified interpretation and the broader health history around it.
Questions about purpose, setting, and preparation can sit alongside the decision workbook’s structured reflection prompts, but reflective work cannot replace assessment of medical or psychiatric risk.
01–04 · A screening sequence
-
Document the full history.
Include cardiovascular history, psychiatric history, allergies, past reactions, and the complete list of medications and supplements.
-
Review relevant assessments.
Where indicated, discuss ECG findings, liver function, and other clinically relevant information with licensed clinicians.
-
Test the provider’s clarity.
Ask how exclusions, medication concerns, monitoring, and emergency escalation are handled in practice—not simply whether they are “covered.”
-
Leave room for “not now.”
A responsible process makes it possible to pause, seek more information, or decide not to proceed without pressure.
During an acute period
Monitoring is a standard, not a promise.
Acute monitoring should be understandable before someone enters a setting. That means knowing who is present, what they observe, how often vital signs are checked, what happens if symptoms change, and how emergency support is reached.
The CDC’s general approach to risk assessment emphasizes identifying hazards and considering controls. In this context, an emergency plan is only meaningful if it is specific to the place, personnel, available equipment, and access to emergency care.
Emergency protocols
Ask who makes urgent decisions, what procedures are in place, and how the setting communicates with emergency services if care is needed.
Real access to care
Consider travel time, transport arrangements, communications, and whether the location creates a delay between recognizing an emergency and reaching help.
Provider and setting review
Red flags often appear in the questions a setting avoids.
Neither reassuring language nor a polished environment substitutes for screening, monitoring, or emergency readiness. The comparison material on ibogaine and ayahuasca risk differences can help focus questions, but a setting should be able to describe its own practices plainly.
- No meaningful health reviewVague intake, absent medication discussion, or dismissal of cardiac and psychiatric history should prompt caution.
- Unclear emergency accessEmergency protocols that cannot be described, or a remote location without realistic escalation options, are material concerns.
- Pressure to stop medicinesAny instruction to change prescription medication without coordination with a licensed prescriber is a serious warning sign.
- Claims of universal suitabilitySafety-focused providers should acknowledge exclusions, uncertainty, and circumstances that require further clinical review.
A cautious next step
The most responsible answer may be more questions.
Compare a setting’s claims with what it can actually explain: screening, medication review, acute monitoring, emergency protocols, and access to licensed care. If the answers remain unclear, consulting a licensed clinician is the appropriate next step.
For location-specific context, Canadian ibogaine treatment center information may help surface additional questions about oversight and setting; it should not replace individualized medical or legal guidance.
Use the framework for careful questionsCommon screening questions
Keep the questions concrete.
What should a medication review cover?
A medication review should cover prescribed medicines, over-the-counter products, supplements, and recent substance use. It is especially important where potential cardiac effects, serotonergic medicines, or MAOI interactions may be relevant. A licensed clinician or qualified prescriber is the appropriate person to interpret an individual medication history.
What makes an emergency plan meaningful?
A meaningful emergency plan is specific: it identifies who monitors, what vital signs are monitored, what escalation procedures exist, how emergency services are reached, and whether transportation to emergency care is realistically available.
Can a screening checklist determine suitability?
No. A checklist can help organize questions, but it cannot determine whether an individual should pursue a substance or setting. That assessment belongs with licensed clinicians who can review medical history, psychiatric history, medications, and current circumstances.